Key Takeaways:
- Argenx (ARGX, Financial) shares dropped ~7% due to FDA warnings about Vyvgart Hytrulo.
- Analyst price targets suggest a potential 45.55% upside.
- GuruFocus estimates indicate a substantial 267.79% upside based on GF Value.
Argenx Shares Impacted by FDA Warning
Argenx (NASDAQ: ARGX) saw its stock tumble by approximately 7% following an alert from the U.S. Food and Drug Administration. The advisory highlights severe risks associated with its Vyvgart Hytrulo treatment, primarily used for managing generalized myasthenia gravis. According to the FDA, the medication could exacerbate conditions such as chronic inflammatory demyelinating polyradiculoneuropathy, triggering a need for further regulatory review.
Wall Street Analysts Forecast
Analyst outlook for argenx SE (ARGX, Financial) remains optimistic despite the recent setback. Twenty-three analysts have set an average one-year price target of $764.20. This suggests an impressive upside potential of 45.55% from the current trading price of $525.06. The forecast range spans from a high of $1,065.00 to a low of $635.00. Investors seeking more granular information can visit the argenx SE (ARGX) Forecast page.
Moreover, the consensus recommendation from a pool of 25 brokerage firms classifies argenx SE (ARGX, Financial) as a "Buy," with an average rating of 1.5. The scale categorically rates stocks from 1, indicating a Strong Buy, to 5, which denotes a Sell.
Insight from GuruFocus Metrics
According to GuruFocus estimates, the projected GF Value for argenx SE (ARGX, Financial) stands at $1931.10. This valuation reflects a remarkable upside of 267.79% from the current price level of $525.06. The GF Value metric serves as GuruFocus's estimation of the stock's intrinsic value, derived from historical trading multiples, past business growth, and forward-looking business performance projections. For a comprehensive understanding, visit the argenx SE (ARGX) Summary page.
